Illumina Inc
ILMN
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
44% downsideOvervalued by 44% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $24.66 Billion |
|---|---|
| Enterprise Value | $26.51 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.48 |
| Beta | 1.42 |
| Outstanding Shares | 153,000,000 |
Return
| Return on Equity | 28.17% |
|---|---|
| Return on Assets | 13.01% |
| Return on Invested Capital | 19.43% |
Valuation & Multiples
| P/E Ratio | 29.23 |
|---|---|
| PEG | 1276.36 |
| Price to Sales | 6.1 |
| Price to Book Ratio | 9.0 |
| Enterprise Value to Revenue | 6.03 |
| Enterprise Value to EBIT | 27.33 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5648▲ 25.86% |
|---|---|
| Total Calls | 745,420▼ 73.74% |
| Total Puts | 421,024▼ 51.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.86%▲ 0.46% |
|---|---|
| Total Invested | $19.20B▼ 7.51% |
| Investors Holding | 868▼ 29.00% |
ESG Score
No data
About Illumina Inc
CEO: Francis deSouza Relevant Senate Committees
Assists tax-writing committees with legislation and provides revenue estimates. Its expertise and analysis directly influence the design and scoring of tax laws, including corporate tax structures and R&D credits, which significantly impact Illumina's financial performance and investment decisions.
Controls taxation, trade, and entitlement spending. Tax policy significantly impacts corporate profitability. Crucially, this committee influences Medicare pricing and reimbursement policies for genomic tests, which is a key factor for market adoption and revenue in the clinical genomics space.
Allocates discretionary federal spending. Its subcommittees directly determine the precise funding for scientific research (e.g., NIH, CDC) and healthcare programs, which translates into direct revenue streams for Illumina's customers and influences their purchasing power for instruments.
Regulates the FDA and NIH. NIH funding is a major driver for Illumina's customer base (research institutions). FDA oversight of diagnostic applications of Illumina's instruments, and general regulation of the biotech/pharmaceutical sectors, directly impacts the company's market and product approvals.
Oversees antitrust laws and intellectual property. Illumina, as a dominant player in its market with significant IP, is directly impacted by patent protection and potential antitrust reviews (e.g., regarding M&A activities like the GRAIL acquisition).
Investigates issues affecting older Americans. Genomics is fundamental to understanding and diagnosing age-related diseases. While advisory, its hearings and policy recommendations can significantly influence research funding and public health initiatives related to aging, impacting demand for Illumina's technologies.
Oversees the Department of Defense and authorizes the annual NDAA. Genomics technology is crucial for military applications such as biodefense, soldier health, and forensics, directly influencing R&D funding and procurement for emerging military technologies relevant to Illumina.
Oversees the Department of Veterans Affairs. Funding decisions directly impact government healthcare contractors and medical device manufacturers. Illumina's genomic instruments are increasingly vital for personalized medicine and diagnostics in VA hospitals.
Members receive classified briefings on global threats. Genomics technology (Illumina's core) has critical applications in biodefense, biosecurity, and intelligence, creating potential for non-public information regarding strategic priorities and funding for such technologies.